Reporting Side Effects in a Clinical Trial

In a clinical trial, telling someone you felt sick is not small talk. It becomes an entry in the study record. Regulators later use that record to decide whether the drug is safe enough to approve.

That is a good reason to report thoroughly. It is also why reporting has its own vocabulary. The words decide what happens next.

The Common Terminology Criteria for Adverse Events, known as CTCAE, is the National Cancer Institute's standard list of side-effect terms used across cancer trials. It defines an adverse event as "any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure."

Read the last clause. May or may not be related.

So you are not being asked to decide whether the study drug caused your rash. You are being asked to say you have a rash. Cause is the investigator's job, and it has its own term. A suspected adverse reaction is "any adverse event for which there is a reasonable possibility that the drug caused the adverse event."

So report the thing you think is unrelated. Report the one you blame on stress or your other medicines. Report the embarrassing one.

CTCAE grades severity from 1 to 5. These are the actual definitions:

• Grade 1: "Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated."
• Grade 2: "Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL."
• Grade 3: "Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL."
• Grade 4: "Life-threatening consequences; urgent intervention indicated."
• Grade 5: "Death related to AE."

ADL means activities of daily living. The two kinds named above are the key to being understood.

CTCAE defines instrumental ADL as "preparing meals, shopping for groceries or clothes, using the telephone, managing money." Self care ADL means "bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden."

Now look at what that does to your answers. "I've been tired" could sit anywhere on the scale. "I skipped the grocery run twice because I could not manage it" points at grade 2. "My husband had to help me shower" points at grade 3.

You do not have to grade yourself. But naming the tasks you could not do gets you graded accurately. Grade is what protocols use to decide whether to continue, hold, or reduce a dose. Ask for your protocol's thresholds in writing.

In trial language, severe and serious are not synonyms. Severity is the grade. Seriousness is defined by what happened.

Federal rules classify an adverse event as serious if it results in death, is life-threatening, requires inpatient hospitalization or makes an existing stay longer, causes persistent or significant incapacity or substantial disruption of normal life functions, or causes a congenital anomaly or birth defect. Life-threatening has its own test: the event "places the patient or subject at immediate risk of death."

So a single overnight admission for fluids can make an event serious even when its grade is modest. If you are hospitalized for any reason while on a trial, tell the study team.

Some reports go to the FDA on a deadline. For a suspected adverse reaction that is both serious and unexpected, the sponsor has 15 calendar days to notify FDA. If it is fatal or life-threatening, that shrinks to 7 calendar days.

"Unexpected" is the interesting word. It means the event is not listed in the investigator's brochure, or is not listed "at the observed specificity or severity." A known side effect that shows up far worse than the brochure describes can count as unexpected.

So precision helps you, not just the study. How bad, how long, and how much it stopped you can separate an expected event from one that triggers a formal report. Ask whether new safety findings will be shared with you, and whether you will be asked to sign an updated consent.

NCI is candid that clinician grading has blind spots. Many side effects are "by their nature personal and difficult for an observer to measure." NCI names nausea, anxiety, and nerve pain. When these get undercounted, researchers can "pick the wrong dose or the wrong treatment schedule."

So NCI built a patient-facing companion to CTCAE: the Patient-Reported Outcomes version, or PRO-CTCAE. The adult version holds 124 items covering 78 symptomatic side effects. You answer about the past 7 days, scored 0 to 4 for how often it happens, how bad it is, and how much it interferes.

If your trial uses it, take it seriously. If it does not, ask how your own account enters the record at all.

A diary entry is research data. It is not a person deciding whether you need to be seen. Use the study team's urgent number.

NCI advises contacting your health care team during cancer treatment for:

• Fever of 100.4 °F (38 °C) or higher, or chills
• "Swelling or redness, especially where a catheter enters your body"
• Sores or white coating in your mouth or on your tongue
• Cough, sore throat, or diarrhea
• Urine that is bloody or cloudy, or pain when you urinate

NCI states plainly that "infections during cancer treatment can be life threatening and require urgent medical attention." If your protocol sets a different temperature threshold, use theirs. For any health emergency, FDA tells trial participants to seek care at a local emergency department.

When you call or write, give these five things:

1. What it is, in ordinary words.
2. The date it started, and whether it has stopped.
3. The worst it got, and when.
4. What you could not do because of it, naming specific tasks.
5. What you took or did for it, including anything over the counter.

Keep a running note between visits. Symptoms that go away get forgotten by clinic day, and a resolved event still belongs in the record.

• What symptoms do you want to hear about immediately rather than at my next visit?
• What grade thresholds would change my dose or hold my treatment?
• If I am hospitalized elsewhere, what do I or the hospital need to send you?
• Will you tell me if a side effect I reported ended up being reported to the FDA?

• National Cancer Institute — Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
• Electronic Code of Federal Regulations — 21 CFR 312.32, IND safety reporting.
• National Cancer Institute — Collecting Patient-Reported Outcomes in Cancer Clinical Trials.
• National Cancer Institute — The PRO-CTCAE Measurement System.
• National Cancer Institute — Infection and Neutropenia during Cancer Treatment.
• U.S. Food and Drug Administration — Conducting Clinical Trials With Decentralized Elements.

Helpful next pages include How Is Your Safety Protected in a Clinical Trial?, Side Effects of Cancer Treatment, Neutropenic Fever During Cancer Treatment, Diarrhea During Cancer Treatment, Rash During Cancer Treatment, Clinical Trial Scan Schedule: What to Ask.